IGF-1 LR3

0.1mg Vial

1mg Vial

2 September 2026Updated 2 September 2026

IGF-1 LR3

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for IGF-1 LR3.

Create free account Member login

Full range of benefits for IGF-1 LR3

Enhances muscle protein synthesis and lean mass accrual

Prolonged IGF-1 activity due to extended half-life vs native IGF-1

Stimulates satellite cell activation and proliferation

Supports post-exercise muscle repair and recovery

Promotes bone formation and remodeling

Increases amino acid uptake into muscle cells

May improve glucose uptake via insulin‑like metabolic effects

Enhances collagen synthesis for connective tissue repair

Exerts anti‑apoptotic effects that support cell survival

Shows potential neuroprotective and neurogenic effects in studies

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 16 known interactions

Synergistic(4)Compatible(4)Monitor(4)Avoid(4)

Works exceptionally well with this peptide

Growth hormone (GH)

Exogenous GH and IGF-1 LR3 produce additive anabolic and growth-promoting effects because GH increases endogenous IGF-1 production while IGF-1 LR3 directly augments IGF-1 receptor signaling.

Insulin

Insulin complements IGF-1 LR3 by enhancing glucose uptake and anabolic signaling, which together increase protein synthesis and glycogen storage.

Testosterone (anabolic-androgenic steroids)

Testosterone and IGF-1 LR3 act via complementary anabolic pathways that can synergistically enhance muscle protein synthesis and lean mass accrual.

Leucine / Branched-chain amino acid (BCAA) supplementation

Leucine or BCAA supplementation activates mTOR-dependent protein synthesis and can potentiate the muscle-building effects of IGF-1 LR3.

All interaction categories

Synergistic (4)

Growth hormone (GH): Exogenous GH and IGF-1 LR3 produce additive anabolic and growth-promoting effects because GH increases endogenous IGF-1 production while IGF-1 LR3 directly augments IGF-1 receptor signaling.
Insulin: Insulin complements IGF-1 LR3 by enhancing glucose uptake and anabolic signaling, which together increase protein synthesis and glycogen storage.
Testosterone (anabolic-androgenic steroids): Testosterone and IGF-1 LR3 act via complementary anabolic pathways that can synergistically enhance muscle protein synthesis and lean mass accrual.
Leucine / Branched-chain amino acid (BCAA) supplementation: Leucine or BCAA supplementation activates mTOR-dependent protein synthesis and can potentiate the muscle-building effects of IGF-1 LR3.

Compatible (4)

Nonsteroidal anti-inflammatory drugs (NSAIDs) e.g., ibuprofen: NSAIDs have no established direct pharmacodynamic interaction with IGF-1 LR3 and are generally compatible for short-term symptomatic use.
Statins (e.g., atorvastatin): Lipid-lowering statins have no well-documented interaction with IGF-1 LR3 and are typically safe to co-administer under routine monitoring.
Vitamin D / multivitamin supplementation: Standard vitamin D or multivitamin supplements have no known adverse interaction with IGF-1 LR3 and are considered compatible.
Antihypertensive agents (ACE inhibitors, ARBs): Common antihypertensive medications have no specific pharmacologic interaction with IGF-1 LR3 and may be co-administered with routine clinical oversight.

Monitor (4)

Insulin and sulfonylureas: IGF-1 LR3 can increase insulin sensitivity and lower blood glucose, so concurrent use with insulin or sulfonylureas requires glucose monitoring and possible dose adjustments to avoid hypoglycaemia.
Exogenous growth hormone (GH): Combined GH and IGF-1 LR3 therapy alters IGF-1 axis feedback and requires monitoring of serum IGF-1, IGFBPs and clinical signs to avoid excessive IGF-1 exposure.
Systemic corticosteroids (glucocorticoids): Glucocorticoids antagonize IGF-1 effects and affect glucose metabolism, so concurrent administration warrants monitoring of metabolic parameters and clinical efficacy.
Thyroid hormone replacement (levothyroxine): Thyroid status influences metabolic rate and IGF-1 responsiveness, so initiating or changing levothyroxine doses during IGF-1 LR3 therapy should prompt thyroid function and clinical monitoring.

Avoid (4)

Active malignancy or history of cancer: Because IGF-1 signaling can promote cellular proliferation and survival, use in patients with active malignancy or recent cancer history requires specialist oncologic evaluation and caution.
Pregnancy and breastfeeding: Safety of IGF-1 LR3 in pregnancy and lactation is not established and potential effects on fetal/infant growth warrant avoidance unless specifically advised by a specialist.
Unstable or severe cardiovascular disease: Anabolic and fluid-retaining effects of IGF-1 LR3 may exacerbate heart failure or worsen cardiac hypertrophy, so use in severe cardiovascular disease requires cardiology review and caution.
Type 1 or insulin-dependent diabetes mellitus: In insulin-dependent diabetes the risk of hypoglycaemia and altered glycaemic control is increased with IGF-1 LR3, so specialist diabetes management and careful dose adjustments are required.